Using patient DNA to optimize therapy in heart failure patients: a move toward perfection.
McLeod
Howard L
HL
UNC Institute for Pharmacogenomics and Individualized Therapy, Division of Pharmacotherapy and Experimental Therapeutics, and the Lineberger Comprehensive Cancer Center, University of North Carolina, Campus Box 7360, Chapel Hill, NC 27599, USA. hmcleod@unc.edu
D002316:Cardiotonic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D004247:DNA; D055106:Genome-Wide Association Study; D005838:Genotype; D006333:Heart Failure / Q000188:drug therapy* / Q000235:genetics*; D006801:Humans; D007703:Peptidyl-Dipeptidase A / Q000235:genetics; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D016896:Treatment Outcome
D002316:Cardiotonic Agents; D004247:DNA; D007703:Peptidyl-Dipeptidase A